Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Steady_T
Unproven MRNA vaccines that were tested on ten dogs and four humans. “While too early in the trial to assess the clinical effects of the vaccine..” we’ll be long developed into a franchise or sold to the highest bidder before that trial ever gets off the ground.
The only way it’s similar is because they’re touting it as “personalized” and a “vaccine” but the methods NWBO has patented for the process of making the personalized dendritic cell vaccine are not the same. They have zero clue what kind of safety profile these MRNA vaccines have.
DCVax has an excellent safety profile. 😁
Lots of scare mongering by this poster as usual. Not a snowballs change in hell you’re correct!
Ignoring the potential of DCVax as a platform technology soon to be validated by the MHRA, The company has IP and patents worth billions. But the self-proclaimed non-investor with an emotional vendetta against this company posts that the valuation of the company will go down to a few hundred thousand dollars? Absolutely laughable.
Another similar approach to GBM. Several years behind. NWBO is plowing the ground.
https://medicalxpress.com/news/2024-05-mrna-cancer-vaccine-triggers-fierce.html
You bought the stock but you don't even know the sticker? Right, a very believable story NOT.
Ohh can it
But somehow LP is still a genius … interesting
Pacer has updated. Docs are submitted.
The shorts in each of those companies took the opportunity to mess with those innovative companies and spread false information because the opportunity to profit was believed to be easy. It's technical, and retail, shorts believe, is stupid.
It works better for small, not yet validated biotechs.
Shorts are a menace to the world. A person can legitimately short a portfolio holding. That's a reasonable way to manage the downside risk if they anticipate something they own was bought at too high a price or if there are macro events that will drive that value down.
But the shorts that manipulate markets and sentiment and spread false light narratives are criminals who leverage our constitutional protections to do harm to society and other investors for profit, spits and giggles.
Very well said!!!!!! This should be posted everywhere!!
Cheers,
BB
Good call.
Evis Hursever was predicted by the eccentric Maverick1 a couple of years ago to be the financier/investor who would back NWBO once it gained approval for DCVax-L.
Approval, cash infusion by above, partnership with (XXX), then uplist, then bye-bye bad guys...........................
I was simply updating that it still had not been filed as flipper indicated it may take some time for it to be picked up by court listener, and because I have access to Pacer.
Oh nonsense. They are all over the place as the microcap level. They are constantly being shorted and attacked by opportunists who think they can take them over like Martin Shkreli. And some have garbage and stay valued highly for years before they crash, because they are being milked by investment funds and their friends taking investor money and playing with them.
Your insight is really not very insightful.
And yeah, there was not an ecosystem developing the CDMO space for this exact product, and so she invested in other people creating it, and they sold, and she bought the retained expertise as part of her spinoff rights so that she could maintain the SAME company effectively, for manufacturing through approval.
But the company owns Flaskworks, and that is the obvious future. They also have the full economic control of Sawston except for those parts that will be used to meet their requirements for local regional development financing, which was low cost, but requires that they provide CDMO services to other, local researchers and companies at Cambridge and in that region.
But yeah, according to shorts it's all criminal even though they are top lawyers who had extremely responsible positions in government and could be making way more money doing other things, with no cares.
Such fricking idiocy. But yeah, it's in your economic interest to spread this nonsense. And of course, UCLA, doctors at top research institutions in immunotherapy including University of Pennsylvania and Brown University, don't agree with you. But you're the anonymous expert online telling people how it really is. Pffft! nonsense! Get lost.
They are likely to be approved. Assuming approval, they have done an immense job keeping their expenses low, their manufacturing scale-up costs low. They are not "dendreon" though the idiot shorts made that bet 10 years ago and they won't let go... but it's a bad bet. This technology is way better at every level, and is breakthrough. Companies do go bankrupt, with fantastic technology as well, and as I said, that is ALWAYS the risk in these small biotechs. ALWAYS. But the opportunity is that IF they succeed, they have the potential to become extremely valuable. Unlike others, I won't predict the market gets it on any event. But someone will, and that will likely transform the conversation. All IMHO.
Nothing changes our fortune outside a large non dilutive big pharma investment. JAMA, TLD, MIA all took us in the reverse direction. Even UK MHRA approvals upside will be short lived, if big pharma announcement doesn’t come shortly thereafter.
I'd never say "any". I've never seen one that had non MD lawyers at the helm. Definitely never saw one that maintained a Going Concern warning with zero institutional holdings for so long. Don't think I can recall one where management didn't have employment agreements in place. Oh, and definitely not one where the CEO owned the CDMO.
Eh…TDD is definitely a pumper.
Boy,
it's always a thrill a minute when dealing with the exceptionally bright psychopaths in this world that seem to pop up in the strangest places, but I guess with the drive to destroy this company and everyone in need of the company's technology, there is the element of murder as relates to those cancer patients that are denied DCVax-L and die an excruciatingly painful death from the side effects of cancer treatments that do not work !!!!
Cheers,
BB
Any small biotech can fail. They can also go from zero to billions. That is the whole point. But your scaremongering is empty. Expected and empty.
For clarity, TDD is not a pumper. Your the idiot spewing BS.
Typical pumper
Why don’t you tell the shorts of Tesla they are I terrier g with transportation.
Tell the shorts of nvidia they are I terrier g with you ability to use chat gbt to make false assumptions about NWBO.
Tell the shorts of MRK that they are interfering of real treatments.
You are a clown
BB it will be interesting to see if Defendants’ new MTD will be limited to arguments not already dismissed. Those are considered “the law of the case” and as such resolved with finality unless a motion specifically seeking reconsideration was filed. (it’s too late but permission could always be granted if sought tho likely that would be denied). I will not be surprised if Defs do not totally abandon dismissed arguments tho they may be revised or corollary to their principle causation attack.
MTD: electronic filing is timely until 11:59:59 pm
says the guy who just gaslight GC....gotta be one of your finest moments DBag.
still haven't posted your position.....crickets
Meanwhile L still hasn't even started one. So much lost time.
>>The UK Paediatric Investigation Plan aims to ensure sufficient data is generated in Dimerix’s ACTION Phase 3 trial to allow for marketing approval for children, should it be successful
>>Our single Phase 3 clinical study, having successfully passed its first efficacy interim analysis is now being rapidly expanded to include new adult and paediatric sites, which will now allow recruiting children down to 12 years old as well as adults,” he says.
https://www.msn.com/en-au/money/markets/dimerix-receives-key-paediatric-investigation-approval-in-uk/ar-AA1nXseR
Interesting, while Walmart announced it will close down 51 healthcare clinics due to high operating costs.
I was being (look it up if you have to) facetious.
So far, these filings have occurred at the 11th+ hour
That was just a bit of sarcasm.
You never read the paper, right? As a matter of fact, the stuff you put here shows us from one perspective the very fact that NWBO is light years ahead of all those vaccines. They are still in a maze trying to figure out which could be the possible exit while NWBO is on a high speed train track.
Next time, read the stuff before you post it, which makes you look smart. Now read the following part first.
https://www.medrxiv.org/content/10.1101/2023.03.12.23287108v1
Zero chance they gave up
I imagine this means they just gave up and they won’t file another MTD. I see no other logical explanation.
Checked Pacer and still not filed yet.
Walgreens expands specialty pharmacy business to gene and cell therapy services
https://qtx.omeclk.com/portal/wts/ue%5EcmQ6fD9-bb0EAaA4DAamwfFjd%5EdzMN9fA7fPsTa
Sell in May, Make my day?
https://images.app.goo.gl/MqqT142uYvZPoWLQA
They did but with external controls that were never officially recognized by regulators and with zero communication with the FDA.
- NWBIO will never data lock
- will never complete the trial
Not all the results.
- will never release results
- will never submit to a journal
This one I got wrong, as I thought it'd be that Italian journal or something comparable. JAMA was a feather in their cap for sure, but I do question relying so heavily on one person for the integrity of the data. I question their read on the data, as do many oncologist.
- will never be published
Only to tiny MHRA
- will never submit to an RA
MHRA requires NICE cooperation.
- will never be approved
With this crew?
- will never get profitable partnerships
- will never make money from approval
- will never submit to the FDA
- will never get approval besides the U.K.
- will never make money in the U.S.
Nothing is cleared until MHRA shows some sign that it's all on the up and up.
>>Looks to me like 6 hurdles cleared, and roughly 6 to go-
Many have passed on, both patients and shareholders.
>>I love watching patiently while each milestone is reached and the FUD narrative is forced change its focus.
you do realize who looks like a buffoon here, right?
post your position.
crickets.........
seems like anytime i ask a pumper to post their position or proof of their buy or average, they can't for some strange reason. It is an easy thing to do without any PII needed.
lmfao.
hahaha, so you're paid, got it.
For the HF manipulators (your handlers) it's "Short in May every day... until we have to pay."
As long as it helps 1 retail GTFO of this garbage.
Satisified now. Post your position shareholder.
do you think you are smart spending your time here as a non shareholder, simple question...
Dude-ess, please...
I think it's eventually going to $0.0005
I don't think they can even get a mere UK approval without running the pediatric trials... Everyone is ignoring this elephant in the room .... PS , from what I've seen, they ARE idiots. IMO
https://www.gov.uk/guidance/procedures-for-uk-paediatric-investigation-plan-pips
you gaslight GC. Looks like dude made an excellent financial decision that worked out for himself. I'm proud of that dude for realizing what POS company this is and working some capital preservation.
Hows that working out? Egg on your face.....yep
They make everything feel like the ether.
Dude it is pathetic. No one wants to own this POS stock and for good reason.
These pumpers need to stop gaslighting retail like they are idiots. I'm convinced the company has plants here to gaslight and give hope to what little retail there are in an pathetic attempt to support the stock price.
Do you feel smart spending your time here?
As a non shareholder. What a fn weirdo thing to do w ones precious time
Institutional Shares (Long) 569,127 - 0.05% of outstanding shares( LOL)
change of -2.55MM shares -82.32% MRQ
Followers
|
1619
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
688477
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |